This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GRTS Gritstone bio (GRTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Gritstone bio Stock (NASDAQ:GRTS) 30 days 90 days 365 days Advanced Chart Get Gritstone bio alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.03▼$0.6352-Week Range N/AVolume61.02 million shsAverage Volume7.01 million shsMarket Capitalization$3.50 millionP/E RatioN/ADividend YieldN/APrice Target$2.17Consensus RatingModerate Buy Company OverviewGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.Read More… Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTS Stock News HeadlinesGritstone Bio sets sale of assets through Bankruptcy CourtDecember 13, 2024 | bizjournals.comGritstone Oncology Inc (GRTSQ)November 27, 2024 | investing.comThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free. April 24, 2025 | Crypto 101 Media (Ad)Gritstone bio, Inc. (GRTSQ)November 22, 2024 | finance.yahoo.comFirm Retention Summary: Gritstone bioNovember 20, 2024 | wsj.comGritstone’s bankruptcy filing reveals biotech’s tough choicesOctober 14, 2024 | bizjournals.comGritstone Oncology Pursues Restructuring Through Chapter 11October 11, 2024 | finance.yahoo.comWhy Gritstone Bio (GRTS) Stock Is Down 64% TodayOctober 11, 2024 | benzinga.comSee More Headlines GRTS Stock Analysis - Frequently Asked Questions How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) released its earnings results on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.12. The company earned $0.92 million during the quarter, compared to analysts' expectations of $2.77 million. Gritstone bio had a negative trailing twelve-month return on equity of 328.51% and a negative net margin of 910.50%. When did Gritstone bio IPO? Gritstone bio (GRTS) raised $85 million in an IPO on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gritstone bio investors own include Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), American Water Works (AWK) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2024Today4/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRTS CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$2.17 High Stock Price Target$5.00 Low Stock Price Target$0.50 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-138,490,000.00 Net Margins-910.50% Pretax Margin-910.50% Return on Equity-328.51% Return on Assets-82.53% Debt Debt-to-Equity Ratio1.83 Current Ratio2.54 Quick Ratio2.54 Sales & Book Value Annual Sales$496,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / BookN/AMiscellaneous Outstanding Shares108,569,000Free Float111,837,000Market Cap$3.50 million OptionableOptionable Beta0.49 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:GRTS) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gritstone bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.